EUVIMEDEUVIMED entdecken
Crossref

Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin

Marina Fayos iD, Jose Tiago Silva iD, Mario Fernández-Ruiz iD, Tamara Ruiz-Merlo iD, Alessandro Visentin iD, Carmelo Loinaz iD, Alejandro Manrique-Municio iD, José María Caso, Jesús González-Olmedo, Isabel Rodríguez-Góncer iD, Francisco López-Medrano iD, Carlos Lumbreras iD und 2 weitere

Transplant Infectious Disease · 2024

DOI: 10.1111/tid.14382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2024. Verfasst von Marina Fayos und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Liver Transplantation, Moxifloxacin, Latent Tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preventive management of tuberculosis in liver transplantation (LT) is challenging due to difficulties in detecting and treating latent tuberculosis infection (LTBI). The aim of this study was to analyze the safety and efficacy of a screening strategy for LTBI with the inclusion of moxifloxacin as treatment.

Methods

We performed a retrospective single‐center study of all LTs performed between 2016 and 2019 with a minimum 4‐year follow‐up and a standardized protocol for the evaluation of LTBI.

Results

Pretransplant LTBI screening was performed in 191/218 (87.6%) patients, and LTBI was diagnosed in 27.2% of them. Treatment for LTBI was administered to 71.2% of the patients and included moxifloxacin in 75.6% of the cases. After a median follow‐up of 1628 days, no cases of active tuberculosis occurred among moxifloxacin‐treated patients. The incidence of Clostridioides difficile (0.46 vs. 0.38 episodes/1000 transplant‐days; p = .8) and multidrug‐resistant gram‐negative bacilli infection (0 vs. 0.7 episodes per 1000 transplant‐days; p = .08) were not significantly higher in comparison to patients who did not receive moxifloxacin.

Conclusion

A preventive strategy based on systematic LTBI screening and moxifloxacin treatment before LT in positive cases appears safe and effective in preventing the development of tuberculosis in LT recipients. However, our findings are limited by a small sample size; thus, larger studies are required to validate our observations. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationMoxifloxacinLatent TuberculosisAntitubercular AgentsHumansRetrospective StudiesMaleMiddle AgedFemaleAdultAgedTransplant RecipientsIncidence

Stichwörter der Autor:innen

Clostridioides difficile infectionantimicrobial prescriptionlatent tuberculosis infectionliver transplantationmoxifloxacinmultidrug‐resistant bacteriatuberculosis

Substanzen

MoxifloxacinAntitubercular Agents

Autor:innen und Institutionen

  • Unit of Infectious Diseases, University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • Antimicrobial Stewardship Team in Hospitalized Patients (PROA-HU12O), University Hospital "12 de Octubre", Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • School of Medicine, Universidad Complutense, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Unit of Hepato-Pancreato-Biliary Surgery and Abdominal Organ Transplantation University Hospital "12 de Octubre", Madrid, Spain.

ORCID-Profile: Marina Fayos, Jose Tiago Silva, Mario Fernández-Ruiz, Tamara Ruiz-Merlo, Alessandro Visentin, Carmelo Loinaz, Alejandro Manrique-Municio, Isabel Rodríguez-Góncer, Francisco López-Medrano, Carlos Lumbreras, José María Aguado, Rafael San-Juan

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Fayos, M., Silva, J. T., Fernández-Ruiz, M., Ruiz-Merlo, T., Visentin, A., Loinaz, C., Manrique-Municio, A., Caso, J. M., González-Olmedo, J., Rodríguez-Góncer, I., López-Medrano, F., Lumbreras, C., Aguado, J. M., & San-Juan, R. (2024). Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin. Transplant Infectious Disease. https://doi.org/10.1111/tid.14382

Vancouver

Fayos M, Silva JT, Fernández-Ruiz M, Ruiz-Merlo T, Visentin A, Loinaz C, et al. Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin. Transplant Infectious Disease. 2024. doi:10.1111/tid.14382

BibTeX
@article{Fayos2024,
  author = {Fayos, Marina and Silva, Jose Tiago and Fernández-Ruiz, Mario and Ruiz-Merlo, Tamara and Visentin, Alessandro and Loinaz, Carmelo and Manrique-Municio, Alejandro and Caso, José María and González-Olmedo, Jesús and Rodríguez-Góncer, Isabel and López-Medrano, Francisco and Lumbreras, Carlos and Aguado, José María and San-Juan, Rafael},
  title = {Efficacy and safety of a preventive strategy against tuberculosis in liver transplantation recipients including the treatment of latent infection with moxifloxacin},
  journal = {Transplant Infectious Disease},
  year = {2024},
  doi = {10.1111/tid.14382}
}
Kostenlos starten →